"The higher the intensity of statins, the higher the effectiveness of preventing cardiovascular disease, which is also associated with diabetes incidence"
Sep 24, 2024
A research team at the Cardiovascular Center at Korea University Guro Hospital (Professor Lee Ji-eun, Choi Ja-yeon, and Na Seung-woon) found that the higher the intensity of taking lipid-lowering drugs (statins), the higher the effectiveness of preventing major cardiovascular diseases and associated with new diabetes rates.
Fatty-lowering agents (statins) are essential drugs for patients with acute myocardial infarction and angina as they lower LDL cholesterol, known as bad cholesterol, and lower the risk of cardio-cerebrovascular diseases such as angina, myocardial infarction, and cerebral infarction by keeping blood vessels healthy. .
Accordingly, the research team followed up with the incidence of new diabetes and major cardiovascular events, total of 6,152 patients who did not have diabetes, underwent coronary intervention for acute myocardial infarction, and were taking statins for acute myocardial infarction (KAMIR) for three years. These patients were taking atorvastatin or rosuvastatin, which is a representative lipolytic (statin).
As a result of analyzing the incidence of new diabetes by dividing the patients into a high-intensity drug (statin) high-intensity drug group (2405) and a medium-intensity drug group (3747), the high-intensity drug group was 7.8%, higher than the moderate-intensity drug group's 5.8%. In addition, the cumulative incidence of major cardiovascular events was significantly lower in the high-intensity group at 11.6%, compared to 14.1% in the moderate-intensity group.
In the analysis of the type and dose of lipid-lowering agents (statins), the higher the dose, the higher the cumulative incidence of new diabetes in patients taking rosuvastatin, while the cumulative incidence of new diabetes in patients taking atorvastatin was not clear. The cumulative incidence of major cardiovascular events by dose of atorvastatin was the lowest at 8.5%, while patients taking 40 mg were 12.0% and patients taking 20 mg and 10 mg were 15.0% and 19.2%, respectively, which decreased significantly as the intensity of the dose increased.
Professor Lee Ji-eun "Through this study, we were able to understand the microscopic characteristics of the intensity of taking lipid-lowering agents (statins)"Statine is a very important drug that effectively lowers the risk of cardiovascular disease, and the medical guidelines also strongly recommend high-intensity statin treatment for patients with acute myocardial infarction. The mechanism of statins' diabetes development is not yet known, and most of the statin-treated patients are already at high risk for diabetes, such as hypertension, hyperlipidemia, obesity, and old age, and it is not yet clear whether statins themselves have the effect of causing diabetes. In addition, high-intensity statins were associated with high incidence of diabetes, but statins are very important depending on individual conditions because they can effectively reduce the risk of cardiovascular diseases such as major cardiovascular event rates, total mortality, recurrence of myocardial infarction, and recapitalization as well as several vascular complications of diabetes. The significance of the study was revealed, saying, "This study will be helpful in detailed customized treatment for individual patients."
Meanwhile, the study was conducted with the support of the Korean Heart Association, and the results of the study were recently published in the SCI-level international journal 『Scientific Reports』.
Fatty-lowering agents (statins) are essential drugs for patients with acute myocardial infarction and angina as they lower LDL cholesterol, known as bad cholesterol, and lower the risk of cardio-cerebrovascular diseases such as angina, myocardial infarction, and cerebral infarction by keeping blood vessels healthy. .
Accordingly, the research team followed up with the incidence of new diabetes and major cardiovascular events, total of 6,152 patients who did not have diabetes, underwent coronary intervention for acute myocardial infarction, and were taking statins for acute myocardial infarction (KAMIR) for three years. These patients were taking atorvastatin or rosuvastatin, which is a representative lipolytic (statin).
As a result of analyzing the incidence of new diabetes by dividing the patients into a high-intensity drug (statin) high-intensity drug group (2405) and a medium-intensity drug group (3747), the high-intensity drug group was 7.8%, higher than the moderate-intensity drug group's 5.8%. In addition, the cumulative incidence of major cardiovascular events was significantly lower in the high-intensity group at 11.6%, compared to 14.1% in the moderate-intensity group.
In the analysis of the type and dose of lipid-lowering agents (statins), the higher the dose, the higher the cumulative incidence of new diabetes in patients taking rosuvastatin, while the cumulative incidence of new diabetes in patients taking atorvastatin was not clear. The cumulative incidence of major cardiovascular events by dose of atorvastatin was the lowest at 8.5%, while patients taking 40 mg were 12.0% and patients taking 20 mg and 10 mg were 15.0% and 19.2%, respectively, which decreased significantly as the intensity of the dose increased.
Professor Lee Ji-eun "Through this study, we were able to understand the microscopic characteristics of the intensity of taking lipid-lowering agents (statins)"Statine is a very important drug that effectively lowers the risk of cardiovascular disease, and the medical guidelines also strongly recommend high-intensity statin treatment for patients with acute myocardial infarction. The mechanism of statins' diabetes development is not yet known, and most of the statin-treated patients are already at high risk for diabetes, such as hypertension, hyperlipidemia, obesity, and old age, and it is not yet clear whether statins themselves have the effect of causing diabetes. In addition, high-intensity statins were associated with high incidence of diabetes, but statins are very important depending on individual conditions because they can effectively reduce the risk of cardiovascular diseases such as major cardiovascular event rates, total mortality, recurrence of myocardial infarction, and recapitalization as well as several vascular complications of diabetes. The significance of the study was revealed, saying, "This study will be helpful in detailed customized treatment for individual patients."
Meanwhile, the study was conducted with the support of the Korean Heart Association, and the results of the study were recently published in the SCI-level international journal 『Scientific Reports』.
|
bellho@sportschosun.com
